[Phenotypical analysis of effector cells on nonspecific cancer cell therapy].
In the present study, we examined the contributions of lymphocyte subpopulations in lymphokine activated killer (LAK) activity. LAK cells prepared from peripheral blood mononuclear cells (PBMC) of healthy donors showed highly cytotoxic activities against target tumor cells. When CD16 and CD56 positive cells in LAK cells were depleted by magnetic cell sorting, their cytotoxic activities were dramatically decreased. In contrast, little change was observed by the depletion of CD3 positive cells, suggesting that CD16 and/or CD56 positive populations, but not CD3 positive populations, including natural killer (NK) cells are the major cell types involved in LAK activity. Indeed, NK-enriched LAK cells prepared by culturing PBMC with IL-2 and OK-432 showed a more potent LAK activity than conventional LAK cells and CD3-activated T cells. These results suggest that selective expansion and activation of CD16 and CD56 positive cells in LAK cells is a useful strategies to improve their anti-tumor potential in nonspecific immunotherapy, and possibly in combination therapy with other target immunotherapies as well.
Sudo
Toshimi
T
Dept. of Gastroenterological Surgery, Tokyo Women's Medical University.
Kobayashi
Yasunobu
Y
Matsushita
Norimasa
N
Shimizu
Kouichi
K
Nakao
Masanobu
M
Tanaka
Yoshinori
Y
Tanigawa
Keishi
K
Aruga
Atsushi
A
D017252:CD3 Complex / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D020014:K562 Cells; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation*; D007694:Killer Cells, Natural / Q000276:immunology; D010844:Picibanil / Q000494:pharmacology
D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2; D010844:Picibanil